Annotating MYC status with 89Zr-transferrin imaging

Jason P. Holland, Michael J. Evans, Samuel L. Rice, John Wongvipat, Charles L. Sawyers, Jason S. Lewis

Research output: Contribution to journalArticlepeer-review

Abstract

A noninvasive technology that quantitatively measures the activity of oncogenic signaling pathways could have a broad impact on cancer diagnosis and treatment with targeted therapies. Here we describe the development of 89Zr-desferrioxamine-labeled transferrin (89Zr- transferrin), a new positron emission tomography (PET) radiotracer that binds the transferrin receptor 1 (TFRC, CD71) with high avidity. The use of 89Zr-transferrin produces high-contrast PET images that quantitatively reflect treatment-induced changes in MYC-regulated TFRC expression in a MYC-driven prostate cancer xenograft model. Moreover, 89Zr-transferrin imaging can detect the in situ development of prostate cancer in a transgenic MYC prostate cancer model, as well as in prostatic intraepithelial neoplasia (PIN) before histological or anatomic evidence of invasive cancer. These preclinical data establish 89Zr-transferrin as a sensitive tool for noninvasive measurement of oncogene-driven TFRC expression in prostate and potentially other cancers, with prospective near-term clinical application.

Original languageEnglish (US)
Pages (from-to)1586-1591
Number of pages6
JournalNature medicine
Volume18
Issue number10
DOIs
StatePublished - Oct 2012
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Annotating MYC status with <sup>89</sup>Zr-transferrin imaging'. Together they form a unique fingerprint.

Cite this